견적문의

HEMEL HEMPSTEAD, ENGLAND--( / )--EUSA Pharma today welcomed a decision by the National Institute for Health and Care Excellence (NICE) to recommend the use of the targeted cancer immunotherapy, QARZIBA® (dinutuximab beta) to treat children with high-risk neuroblastoma within the NHS in England and Wales.i High-risk neuroblastoma is an aggressive form of neuroblastoma - the most common solid tumour of childhood that originates outside of the brain.ii Dinutuximab beta is the first targeted cancer immunotherapy approved for use on the NHS to treat this disease. It has been shown in a post-hoc analysis to improve overall survival (OS) outcomes compared to historically treated patients who did not receive immunotherapy as part of their care. Dinutuximab beta, when used in the maintenance phase of treatment for patients who did not receive prior immunotherapy, is also used to keep this cancer from returning or progressing in some children with high-risk neuroblastoma.ii

“Today’s decision by NICE is a vital step forward in the treatment of young children with this aggressive type of cancer,” said Dr Juliet Gray, Associate Professor in Paediatric Oncology at the Cancer Immunology Centre, University of Southampton. “By harnessing the body’s own immune system, dinutuximab beta has shown it can target and attack this cancer very effectively in some patients. For some children this could mean extra weeks or months with their families, for others it may even lead to them becoming cancer-free for a long period of time.”

Dinutuximab beta is a monoclonal antibody (a type of protein) that binds to a specific target which is overexpressed on neuroblastoma cells, called GD2.iii This induces dual immune mechanisms that then enable the immune system to lead the destruction of neuroblastoma cancer cells.ii In the key phase III clinical study (APN311-302), a post hoc comparison of dinutuximab beta, used in the maintenance phase of the first-line treatment of high-risk neuroblastoma (n=367) , showed improved survival outcomes, with a 12% improvement in OS rate at three years versus using no immunotherapy in a historical control group of similar patients (n=450).ii The dinutuximab beta treated patients had an OS rate of around 65% at 5 years versus 50% compared to the historical control group (p=<0.0001).ii

Tony Heddon, Chair of Neuroblastoma UK commented: “Ensuring that children and families facing high-risk neuroblastoma have access to the medicines and care they need is absolutely critical. Today’s recommendation is a bold and forward-thinking decision from NICE and we applaud them, EUSA Pharma and all those across the community who have worked together to make this medicine available. This decision offers the hope that these children with high-risk neuroblastoma, may now have a better future in front of them.”

On average, every week, two families in the UK will learn that their child has neuroblastoma, with approximately 100 children diagnosed each year.iv It is the most frequently-occurring solid tumour in infants under the age of one, accounting for around a fifth (22%) of all cancers diagnosed at this age.v Children with high-risk disease to whom this approval applies, account for approximately 40% of all neuroblastoma cases.vi Children with high-risk neuroblastoma typically undergo many rounds of complex and intensive treatment, usually comprising several cycles of chemotherapy, surgery, stem cell transplant and radiotherapy.vii

The recommendation from NICE within its Final Appraisal Determination (FAD) is that dinutuximab beta be used as an option for treating high-risk neuroblastoma after at least a partial response from induction chemotherapy, followed by myeloablative therapy and stem cell transplant in people aged 12 months and over, if the person has not had previous anti-GD2 immunotherapy.i

Lee Morley, CEO of EUSA Pharma added: “Today’s decision is the result of strong collaboration between NICE, EUSA Pharma and the neuroblastoma community, who have each worked tirelessly to ensure that every eligible child has the option to benefit from this potentially life-changing treatment. Our long-standing commitment has always been to secure access to dinutuximab beta for all eligible children with high-risk neuroblastoma, across the UK and today’s decision is a key part of that journey. Beyond England and Wales, we are continuing to work closely with the Scottish and Northern Irish health authorities with the aim of making this medicine available in those countries as quickly as possible.”

About dinutuximab beta

How it works

Dinutuximab beta is a monoclonal antibody (a type of protein) that has been designed to recognise and attach to a tumour-associated carbohydrate structure, called GD2, which is present in high amounts on the surface of neuroblastoma cells.ii When dinutuximab beta attaches to the neuroblastoma cells, it induces dual immune system mechanisms (the complement-dependant and antibody-dependant cell-mediated immune pathways) and makes them a target for the body’s immune system. This then mounts an attack to kill the cancer cells, using the body’s natural killer immune cells, and the complement protein system.ii

Its development and approval

Dinutuximab beta is the result of a considered science-pharma collaboration. Dinutuximab beta was developed by Apeiron Biologics with a number of partners (in particular the SIOPEN academic neuroblastoma group) and acquired by EUSA Pharma in 2016, to bring the treatment to market. Dinutuximab beta received European approval in May 2017, first under the brand names dinutuximab beta Apeiron and Dinutuximab beta EUSA and subsequently under its new name, QARZIBA®, approved by the European Medicines Agency in November 2017.iii

How it is taken

Dinutuximab beta is given as an infusion (drip) into a vein. Each course of treatment with the medicine is given for 5 or 10 days every 35 days. It is given for a total of 5 courses. The recommended dose depends on the patient’s weight and height.iii

Data supporting its use

Dinutuximab beta has been investigated in a number of clinical trials for high-risk neuroblastoma.ii During the NICE appraisal, the primary clinical evidence came from APN311-302, a multinational, open-label, randomised, controlled Phase III trial comparing dinutuximab beta plus isotretinoin (n=189) with dinutuximab beta plus isotretinoin plus interleukin-2 (n=190).i,ii The primary outcome in the trial was event-free survival at three years (disease progression or relapse, death and secondary tumour defined as events) with OS, overall response, and incidence of relapsed or refractory disease included as secondary outcomes.ii This study consisted of up to five different comparison phases, one of which was treatment with dinutuximab beta with or without interleukin-2 (IL-2) during the maintenance phase , in the first line setting.ii

In APN311-302, the 3-year event free survival (primary endpoint) showed rates of 55% without IL-2 and 61% with IL-2 (p=0.3202) while the 3-year OS rates were 64% and 69%, respectively (p=0.6114).i A comparison to an historical control group obtained from an earlier patient enrolment within the APN311-302 study (between 2002 and 2010) was performed using 450 high-risk neuroblastoma patients, who did not receive immunotherapy. Given the relatively high number of patients it is expected that these patients are representative of patients with high-risk neuroblastoma seen in clinical practice during this period. This comparison showed that the percentage of patients that were still alive after three years of follow-up was 12% higher after dinutuximab beta treatment (with or without IL-2) than for patients who did not receive immunotherapy, a difference considered clinically relevant.ii It also showed an OS rate of around 65% at 5 years with dinutuximab beta versus 50% in the historical control group (p=<0.0001).ii

At marketing authorisation, the European Medicines Agency considered that the available data set was not comprehensive and that measures were necessary to generate additional efficacy and safety data. EUSA Pharma is committed to this and is continuing to collect further data to widen the body of efficacy and safety information available on this medicine.ii

Side effects

Side effects with dinutuximab beta are common. In general, the most common side effects with dinutuximab beta (which may affect more than 7 in 10 people) are pyrexia (fever) and pain. Other side effects (which may affect more than 3 in 10 people) are hypersensitivity (allergy), vomiting, diarrhoea, capillary leak syndrome (leakage of fluid from blood vessels that can cause swelling and a drop in blood pressure) and hypotension (low blood pressure).iii

In the APN311-302 study, 98.9% of patients (362 of 366) in both treatment group experienced toxicities. Serious adverse events were reported more frequently in patients receiving IL-2 (46% of 183 patients) compared to patients not receiving IL-2 (27% of 183 patients). Serious adverse events leading to discontinuation of treatment were more frequent in the IL2 arm than the group without IL2,17% vs 6% of patients, respectively.ii

Further details of side effects can be found in the Summary of Product Characteristics on the EMA websiteviii

About EUSA Pharma

Founded in March 2015, EUSA Pharma is a specialty pharmaceutical company with commercial operations across Europe and the USA and a wider distribution network in approximately 40 further countries. The management team comprises highly-experienced pharmaceutical professionals with a proven track record of successfully identifying, developing and commercialising innovative medicines that advance patient care and improve their wellbeing. For more information visit:

References

i NICE Final Appraisal Determination (FAD) for dinutuximab beta for treating neuroblastoma.

ii QARZIBA Public Assessment Report. Available at Accessed July 2018

iii QARZIBA EPAR - Summary for the public. Available at Accessed July 2018

iv Cancer Research UK: About Neuroblastoma. Key fact available at Accessed July 2018.

v Cancer Research UK: Children’s cancers. Children’s SNS tumour incidence. Available at Accessed July 2018.

vi NICE dinutuximab beta committee papers. Available at Accessed July 2018.

vii Cancer Research UK - neuroblastoma treatment by risk group. Key fact available at Accessed July 2018.

viii QARZIBA SmPC - Available at Accessed July 2018.

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to EUSA Pharma. Email: safety@eusapharma.com Fax: +44(0)3305 001167

View source version on businesswire.com:Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution network

TORONTO--( / )--Cyclica, a neo biotech company, announced today the close of a CAD$23M Series B 미추홀구홀덤바 박시후유출닷컴 round of financing. The round was led by Drive Capital with participation from Chiesi Farmaceutici, GreenSky Capital, and 외국야동사이트 TORONTO--(FREESEX 아사다마오의상 of Cyclica's management team.

Cyclica is decentralizing the discovery of better medicines by combining its deep roots in Artificial Intelligence (AI) and protein biophysics with an innovative FREESEX 안녕하세요못된손 business model. To drive sustainable 미추홀구홀덤바 progress in reducing attrition rates and timelines to the clinic, Cyclica believes that an avant-garde and holistic approach to drug discovery, both scientifically and commercially, is required.

Funding from the round will 미추홀구홀덤바 support continued innovation around Cyclica’s integrated proteome-wide drug discovery platform, and will expand its application within 웃긴대학 Fundingpharma FREESEX industry. It will also support expansion into adjacent sectors, such as agro-chemicals.

The financing will 미추홀구홀덤바 꽃무늬프릴비키니 accelerate Cyclica’s 미추홀구홀덤바 도트프릴비키니 commercial strategy to create and own hundreds of drug discovery programs across multiple therapeutic areas. These programs are 미추홀구홀덤바 언데드흑마 created via spin-outs and FREESEX 흑마법사 joint ventures with 떡마차 Thetier research institutions, facilitated largely through the Cyclica Academic Partnership Program (“CAPP”).

Propelled by a rapidly growing portfolio of 스트립쇼 Propelledthan 30 active and advancing drug discovery programs, Cyclica will continue to spark innovation through a combination of venture creation and partnerships with early-stage and emerging biotech companies. Recent partnerships include EntheogeniX 미추홀구홀덤바 옷벗으면 Biosciences, NineteenGale FREESEX 옷버스 Therapeutics, Rosetta Therapeutics, the Rare Diseases Medicine Accelerator, FREESEX a joint venture with Mannin Research, and 미추홀구홀덤바 \혼자보세요,혼자보세요 two 미추홀구홀덤바 sexyzone stealth JVs encompassing over FREESEX 예쁜치마 50 programs across multiple therapeutic areas.

Srinivas Rao, MD, FREESEX PhD, CEO of EntheogeniX Biosciences and CSO of ATAI Life Sciences had this to say: “Cyclica’s computational platform shaved many months off of our timeline, and allowed us to achieve our objective of generating completely novel, synthetically tractable lead-like 오카모토 SrinivasThe flexibility, speed, and passion of the FREESEX 여자친구만드는법 Cyclica 미추홀구홀덤바 여자랑친해지는법 team around drug design is readily apparent, and this enthusiasm has been a key driver of our rapid development.”

“What attracted us to Cyclica was their creative and unique business FREESEX 모노키니 model,” said Molly Bonakdarpour, 미추홀구홀덤바 여자친구랑여행갈만한곳 Partner at Drive Capital. FREESEX 비키니왁싱하는법 “They’ve created a diversified portfolio FREESEX 당일놀러갈만한곳 of assets across therapeutic indications through a partnership model. At the same time, they continue to collaborate with multinational companies. These companies represent strategic partnership options for the Cyclica portfolio. Cyclica is enabling world-class biotech companies while increasing their probability of success.”

“At the very core of Cyclica’s ethos is the steadfast desire to help patients by advancing the discovery and FREESEX veet development of better medicines by taking a holistic yet personalized approach,” said Naheed Kurji, Co-Founder, President and CEO of Cyclica. “We are driving this ambitious vision FREESEX forward by partnering with hyper innovative biotech companies that are 나나우미나나 “Atin sound science, and we are enabling them with our 미추홀구홀덤바 대구비키니라인제모 platform, our team of applied scientists, and our network of external partners. By creating new companies through spin-outs and joint ventures and helping them scale, we are in effect creating the biotech pipeline of the FREESEX future."

About 미추홀구홀덤바 엘유뷔판매쇼핑몰 AboutFREESEX 컴퓨터공유하는방법

Cyclica is 미추홀구홀덤바 공유 the first company to approach polypharmacology with a structure-based, AI-augmented in silico FREESEX 컴퓨터두대공유 discovery platform, centred on Ligand Design and Ligand Express. Powered by MatchMaker™, a proprietary deep learning proteome screening technology, and POEM™, an innovative supervised learning technology for predicting molecular properties, Cyclica’s platform is suited uniquely to the design of novel, drug-like chemical matter by simultaneously prioritizing compounds based on their on- and off-target polypharmacological profiles as well as their developmental properties. With a world-class team that has deep roots in FREESEX 윈도우7네트워크공유 the industry, FREESEX 네트워크연결이안될때 a first-in-class platform, and an innovative decentralized partnership model, Cyclica is creating medicines with greater precision for unmet patient needs.

View source version on businesswire.com:Korea Newswire distributes your FREESEX 미추홀구홀덤바 코믹댄스동영상 Viewacross every media channels FREESEX 밥공유아이디 through the industry’s largest press release distribution network